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Abstract
Synthesis, characterization and cytotoxic activities of ten benzothiazole-piperazine derivatives
were reported. In vitro cytotoxic activities of compounds were screened against hepatocellular
(HUH-7), breast (MCF-7) and colorectal (HCT-116) cancer cell lines by sulphorhodamine B assay.
Based on the GI50 values of the compounds, most of the benzothiazole-piperazine derivatives
are active against HUH-7, MCF-7 and HCT-116 cancer cell lines. Compound 1d is highly
cytotoxic against all tested cancer cell lines. Further investigation of compound 1d by Hoechst
Staining and Fluorescence-Activated Cell Sorting Analysis (FACS) revealed that this compound
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Introduction
Cancer, remaining to be a major health problem today, is caused
by abnormal cell division without control. Cancer cells are able to
spread into other parts of the body through blood and lymph
system. Although there are many advances in treatment of cancer,
most of anticancer drugs still need to be improved because of
various limitations like emergence of drug resistance, low
therapeutic index and lack of selectivity. Thus, cancer studies
continue to develop new anticancer medicines, targeted therapies,
monoclonal antibodies, etc.
Benzothiazole derivatives were reported to be highly cytotoxic
against HCT-116 (colorectal cancer cell line)1, MCF-7 (breast
cancer cell line)2, U937 and THP-1 (leukemia cancer cell lines)3.
Isatin Mannich bases with benzothiazole moiety were reported as
potential anti-breast cancer drugs. Flow cell cytometry showed
that most active compound in series resulted in cell cycle arrest at
G2/M phase4. Thiourea derivatives bearing benzothiazole moiety
were reported to be cytotoxic against MCF-7 and HeLa breast
cancer cell lines. Most active derivatives of the series were
proven to act by damaging DNA with alkaline Comet assay5.
2-(4-Aminophenyl)benzothiazoles with cytotoxic activity against
MCF-7 (breast) and IGROV-1 (ovarian) cancer cell lines caused
generation of DNA adducts which induce apoptosis6.
Piperazine ring is another value for anticancer drug candidates.
Piperazinobenzopyranones were reported as breast cancer resist-
ance protein inhibitors which are usually responsible with
demolished effect of anticancer medication7. Piperazine ring
carrying nucleoside analogues were evaluated for their cytotoxic
activities on various cancer cell lines and most active compounds
were further analyzed to evaluate mechanism of action. Agents
caused induction of senescence-associated cell death through the
inhibition of some kinase proteins8. In addition, Yarim and her
co-workers previously reported various piperazine derivatives
with high cytotoxic activity against liver (HUH-7, FOCUS,
MAHLAVU, HepG-2, Hep-3B), breast (MCF-7, BT20 and
T47D), colon (HCT-116), gastric (KATO-3), cervix (HeLa) and
endometrial (MFE-296) cancer cell lines9–11.
According to anticancer activity studies of benzothiazole-
piperazine backbone, arylsulphonamides and arylthiol derivatives
have potent cytotoxicity against a large scale of cancer cell
lines such as breast (MCF-7), hepatocellular (HepG-2), prostate
(DU-145) cancers and CD4+ human acute T-lymphoblastic
leukaemia (CCRF-CEM)12,13.
In this study, with the aid of aforementioned studies, we
reported the synthesis, purification and characterization of novel
compounds which contain benzothiazole-piperazine backbone in
their molecular structure. These compounds were tested for their
cytotoxic activities against hepatocellular (HUH-7), breast
(MCF-7) and colorectal (HCT-116) cancer cell lines with
sulphorhodamine B assay. The advanced analysis, Hoechst
staining and fluorescence-activated cell sorting analysis were




All chemicals and reagents used in current study were of
analytical grade. The reactions were monitored by thin layer
chromatography (TLC) on Merck pre-coated silica GF254 plates.
Melting points (C) of the compounds were determined by using a
Mettler Toledo FP62 capillary melting point apparatus (Mettler-
Toledo, Greifensee, Switzerland) and are uncorrected. Infrared
spectra were recorded on a Perkin-Elmer Spectrum One series FT-
IR apparatus Version 5.0.1 (Perkin Elmer, Norwalk, CT), using
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potassium bromide pellets, the frequencies were expressed in
cm1. Elemental analyses were performed on LECO 932 CHNS
(LECO-932, St. Joseph, MI) instrument. UV spectra were
recorded on Evolution 201/220 UV-visible spectrophotometer
and ethanol was used as solvent. The 1H-NMR spectra were
recorded with a Varian Mercury-400 FT-NMR spectrometer
(Varian Inc., Palo Alto, CA), using tetramethylsilane (TMS) as the
internal reference, with chloroform (CDCl3) as solvent, the
chemical shifts were reported in parts per million (ppm).
Coupling constants were recorded in Hertz (Hz).
General procedure for synthesis of 2-chloro-N-(6-methylben-
zothiazol-2-yl)acetamide (1)
2-Amino-6-methylbenzothiazole (0.012 mol (2 g)) was dissolved
in 42 ml benzene: triethlyamine mixture (20:1)14. Later, acetyl-
ation was performed with 0.011 mol (0.87 ml) chloroacetyl
chloride in room temperature. Because of the highly reactant
nature of chloroacetyl chloride, it was added slowly in small
amounts. Reaction was monitored by TLC with silica gel plate
and benzene:methanol (9:1) mobile phase mixture. Reaction
completed in four days at room temperature. Precipitated crude
product was filtered, washed with benzene and dried. Ethanol
crystallization gave pure product.
General procedure for synthesis of N-(6-methylbenzothiazol-2-yl)-
2-(4-substitued piperazinyl)acetamide derivatives (1a–f)
N-(6-methylbenzothiazol-2-yl)-2-(4-substituedpiperazinyl)aceta-
mides were synthesized in acetone by the reaction of
0.0025 mol (0.602 g) 2-chloro-N-(6-methylbenzothiazol-2-
yl)acetamide and 0.0025 mol of suitable piperazine, in presence
of 0.0025 mol (0.345 g) anhydrous K2CO3. Reactions were
monitored by TLC with silica gel plate and benzene:methanol
(9:1) mobile phase mixture. Reactions completed in two days
at room temperature. Potassium carbonate was removed by
filtration. After evaporation of acetone, precipitated products were
recrystallized from absolute ethanol or acetone:distilled water
mixture.
General procedure for synthesis of 2-chloro-N-(6-ethoxyben-
zothiazol-2-yl)acetamide (2)
2-Amino-6-ethoxybenzothiazole (0.012 mol (2.22 g)) was
dissolved in 42 ml benzene: triethylamine mixture (20:1)14.
Later, acetylation was performed with 0.013 mol (0.78 ml)
chloroacetyl chloride at room temperature. Because of the
highly reactant nature of chloroacetyl chloride, it was added
slowly in small amounts. Reaction was monitored by TLC with
silica gel plate and benzene:methanol (9:1) mobile phase mixture.
Reaction completed in four days at room temperature.
Precipitated crude product was filtered, washed with benzene
and dried. Ethanol crystallization gave pure product.
General procedure for synthesis of N-(6-ethoxybenzothiazol-2-yl)-
2-(4-substitued-piperazinyl)acetamides (2a–d)
N-(6-ethoxybenzothiazol-2-yl)-2-(4-substituedpiperazinyl)aceta-
mides were synthesized in acetone by the reaction of 0.0025 mol
(0.677 g) 2-chloro-N-(6-ethoxybenzothiazol-2-yl)acetamide and
0.0025 mol of suitable piperazine, in presence of 0.0025 mol
(0.345 g) anhydrous K2CO3. Reactions were monitored by
TLC with silica gel plate and benzene:methanol (9:1) mobile
phase mixture. Reactions completed in two days at room
temperature. Potassium carbonate was removed by filtration.
After evaporation of acetone, precipitated products were
recrystallized from absolute ethanol or acetone:distilled water
mixture.
Cytotoxicity studies
The cytotoxic activity of the synthesized compounds was
investigated on liver (HUH-7), breast (MCF-7) and colon
(HCT-116) cancer cell lines, by means of sulphorhodamine B
(SRB) assays in triplicate. Serial dilutions from 100mM to 2.5mM
were used, 5-fluorouracil (5-FU) was the reference compound.
Cell culture
The human cancer cell lines were grown in Dulbecco’s Modified
Eagle’s Medium (DMEM) supplemented with 10% fetal bovine
serum (FBS) and 1% penicillin. Each cell line was maintained in
an incubator at 37 C supplied with 5% CO2 and 95% air.
NCI-60 sulphorhodamine B (SRB) assay
Cancer cells (range of 2000 cell/well to 5000 cell/well) were
inoculated into 96-well plates in 200ml of media and incubated in
37 C incubators containing 5% CO2 and 95% air. After a 24 h
incubation period, one plate for each cell line was fixed with
100ml 10% ice-cold trichloroacetic acid (TCA). This plate
represents the behaviour of the cells just prior to drug treatment
and is accepted as the time-zero plate. The compounds to be
tested were solubilized in DMSO to a final concentration of
40 mM and stored at +4 C. While treating the cells with the
compounds, the corresponding volume of the compound was
applied to the cell to achieve the desired drug concentration and
diluted through serial dilution. After drug treatment, the cells
were incubated in 37 C incubators containing 5% CO2 and 95%
air for 72 h. Following the termination of the incubation period
after drug treatment, the cells were fixed with 100 ml 10% ice-cold
TCA and incubated in the dark at +4 C for 1 h. Then the TCA
was washed away with ddH2O five times and the plates were left
to air dry. For the final step, the plates were stained with 100ml of
0.4% sulphorhodamine B (SRB) solution in 1% acetic acid
solution. Following staining, the plates were incubated in dark for
10 min at room temperature. The unbound dye was washed away
using 1% acetic acid and the plates were left to air dry. To
measure the absorbance results, the bound stain was then
solubilized using 200ml of 10 mM Tris-Base. The OD values
were obtained at 515 nm.
Hoechst staining analysis
Cells were seeded on coverslips in 6-well plates. After
overnight culture, cells were exposed to compounds at a
concentration of their GI50 values for 72 h. To determine nuclear
condensation by Hoechst 33258 (Sigma-Aldrich) staining, cover-
slips were washed twice with icecold PBS, fixed in 1 ml of
cold methanol for 10 min, and then incubated with 3 Ig/ml of
Hoechst 33258 for 5 min in darkness. The coverslips were then
rinsed with distilled water, mounted on glass microscopic slides
using 50% glycerol, and examined under fluorescent microscopy
(40).
Fluorescence-activated cell sorting analysis
Human cancer cell line (HUH-7) of interest were inoculated into
100-mm culture dishes (300 000 cells/dish). Twenty-four hours
later, cells were then treated with the desired compounds
according to their GI50 values and incubated for 72 h. Cells
were then collected by trypsinization and the pellets were fixed in
ice-cold 70% ethanol and stored at 20 C. Before the analysis,
the samples were stained with MUSE cell cycle reagent (contains
propidium iodide solution) according to the manufacturer’s
protocol. Cell cycle analysis was conducted with MUSE cell
cycle analyzer.



































White powder, 48% (0.417 g), m.p. 121.9 C (reported:
122–124 C). UV (MeOH, lmax, nm); 291 (log ": 4.21). FT-IR
(KBr, cm1); 3333 (N–H), 3058 (C–H, aromatic), 2908 (C–H,
aliphatic), 1707 (C¼O, amide), 1605 (C¼C, aromatic), 1242
(C–N), 1056 (C–O)15. 1H-NMR (CDCl3, ppm); 2.48 (s, 3H,
Ar–CH3), 2.86 (t, 4H, piperazine H2,6, J¼ 4.8 Hz), 3.18 (bs, 4H,
H3,5), 3.36 (s, 2H, –COCH2N–), 3.88 (s, 3H, –OCH3), 6.89 (d, 1H,
phenyl H2, J¼ 9.2 Hz), 6.94–6.98 (m, 2H, phenyl H3,5), 7.02–7.06
(m, 1H, phenyl H4), 7.25–7.28 (m, 1H, benzothiazole H5), 7.62
(s, 1H, benzothiazole H7), 7.68 (d, 1H, benzothiazole H4,
J¼ 8 Hz), 10.47 (bs, 1H, –NHCOCH2–). Anal Calcd for
C21H24N4O2S (396.506): C, 63.61; H, 6.10; N, 14.13; S, 8.09.
Found: C, 63.52; H, 6.14; N, 14.25; S, 8.04.
N-(6-methylbenzothiazol-2-yl)-2-[4-(2-methoxyethyl)piperaziny-
l]acetamide (1b)
Cream colored, shiny powder. 12% (0.099 g), m.p. 81.1 C. UV
(MeOH, lmax, nm); 292 (log ": 4.25). FT-IR (KBr, cm
1); 3120
(N–H), 3050 (C–H, aromatic), 2946 (C–H, aliphatic), 1697
(C¼O, amide) 1607 (C¼C, aromatic), 1259 (C–N), 1067 (C–O).
1H-NMR (CDCl3, ppm); 2.46 (s, 3H, Ar-CH3), 2.62 (t, 2H,
–NCH2CH2–, J¼ 5.2 Hz), 2.69 (bs, 8H, piperazine), 3.27 (s, 2H,
–COCH2N–), 3.36 (s, 3H, –OCH3), 3.51 (t, 2H, –CH2OCH3,
J¼ 5.2 Hz), 7.23–7.26 (m, 1H, benzothiazole H5), 7.61 (s, 1H,
benzothiazole H7), 7.67 (d, 1H, benzothiazole H4, J¼ 8 Hz),
10.39 (bs, 1H, –NHCOCH2–). Anal Calcd for C17H24N4O2S
(348.463): C, 58.26; H, 7.48; N, 15.99; S, 9.15. Found: C, 58.22;
H, 7.44; N, 15.97; S, 9.18.
N-(6-methylbenzothiazol-2-yl)-2-(4-cyclohexylpiperazinyl)aceta-
mide (1c)
White powder. 2.8% (0.026 g), m.p. 181.3 C. UV (MeOH, lmax,
nm); 289 (log ": 4.25). FT-IR (KBr, cm1); 3261 (N–H), 2932
(C–H, aromatic), 2853 (C–H, aliphatic), 1703 (C¼O, amide),
1605 (C¼C, aromatic), 1262 (C¼N). 1H-NMR (CDCl3, ppm);
1.09–1.27 (m, 6H, cyclohexyl), 1.63–1.66 (m, 1H, cyclohexyl),
1.80–1.88 (m, 4H, cyclohexyl), 2.48 (s, 4H, piperazine H2,6), 2.48
(s, 3H, Ar–CH3), 2.67 (s, 4H, piperazine H3,5), 3.26 (s, 2H,
–COCH2N–), 7.25–7.27 (m, 1H, benzothiazole H5), 7.62 (s, 1H,
benzothiazole H7), 7.68 (d, 1H, benzothiazole H4, J¼ 8 Hz),
10.41 (bs, 1H, –NHCOCH2–). Anal Calcd for C20H28N4OS
(372.528): C, 64.14; H, 8.07; N, 14.96; S, 8.56. Found: C, 64.12;
H, 8.08; N, 14.97; S, 8.58.
N-(6-methylbenzothiazol-2-yl)-2-[4-(pyridin-4-yl)piperazinyl]a-
cetamide (1d)
White powder. 22% (0.195 g), m.p. 100.8 C. UV (MeOH, lmax,
nm); 293 (log ": 4.13). FT-IR (KBr, cm1); 3192 (N–H), 3050
(C–H, aromatic), 2842 (C–H, aliphatic), 1703 (C¼O, amide),
1603 (C¼C, aromatic), 1212 (C–N). 1H-NMR (CDCl3, ppm);
2.48 (s, 3H, Ar-CH3), 2.78 (t, 4H, piperazine H2,6, J¼ 5.4 Hz),
3.45 (t, 4H, piperazine H3,5, J¼ 4.8 Hz), 3.60 (s, 2H, –COCH2N–
), 6.68–6.70 (dd, 2H, pyridine H3,5, J1¼ 1.6 Hz, J2¼ 5 Hz), 7.26–
7.28 (m, 1H, benzothiazole H5), 7.63 (s, 1H, benzothiazole H7),
7.67 (d, 1H, benzothiazole H4, J¼ 8.4 Hz), 8.30–8.32 (dd, 2H,
pyridine H2,6, J1¼ 1.6 Hz, J2¼ 5.2 Hz), 10.37 (bs, 1H,
–NHCOCH2–). Anal Calcd for C19H21N5OS (367.468): C,




White powder. 16% (0.196 g), m.p. 243.8 C. UV (MeOH, lmax,
nm); 293 (log ": 4.25). FT-IR (KBr, cm1); 3278 (N–H), 3017
(C–H, aromatic), 2893 (C–H, aliphatic), 1707 (C¼O, amide), 1605
(C¼C, aromatic), 1240 (C–N). 1H-NMR (CDCl3, ppm); 2.48
(s, 3H, Ar–CH3), 2.80 (t, 4H, piperazine H2,6, J¼ 4.8 Hz), 3.27
(t, 4H, piperazine H3,5, J¼ 5.2 Hz), 3.35 (s, 2H, –COCH2N–),
6.74–6.77 (dd, 1H, phenyl H2, J1¼ 3.2 Hz, J2¼ 8.6 Hz), 6.98 (d,
1H, phenyl H6, J¼ 3.2 Hz), 7.25–7.26 (m, 1H, benzothiazole H5),
7.30 (d, 1H, phenyl H5, J¼ 9.2 Hz), 7.62 (s, 1H, benzothiazole H7),
7.68 (d, 1H, benzothiazole H4, J¼ 8.4 Hz), 10.33 (bs, 1H,
–NHCOCH2–). Anal Calcd for C20H20Cl2N4OS (435.37): C,




Cream-colored powder. 12% (0.115 g), m.p. 189.6 C. UV
(MeOH, lmax, nm); 288 (log ": 4.27). FT-IR (KBr, cm
1); 3100
(N–H), 3038 (C–H, aromatic), 2929 (C–H, aliphatic), 1692
(C¼O, amide), 1607 (C¼C, aromatic), 1271 (C–N). 1H-NMR
(CDCl3, ppm); 2.47 (s, 3H, Ar–CH3), 2.54 (bs, 4H, piperazine
H3,5), 2.66 (bs, 4H, piperazine H2,6), 3.27 (s, 2H, –N–CH2–), 3.51
(s, 2H, –COCH2N–), 7.22–7.28 (m, 4H, phenyl), 7.29–7.31
(m, 1H, benzothiazole H5), 7.61 (s, 1H, benzothiazole H7), 7.68
(d, 1H, benzothiazole H4, J¼ 8.4 Hz), 10.4 (bs, 1H,
–NHCOCH2–). Anal. calcd. for C21H23ClN4OS (414.952): C,




Honey colored irregular crystals. 36.5% (0.375 g), m.p. 146.7 C.
UV (MeOH, lmax, nm); 294 (log ": 4.18). FT-IR (KBr, cm
1);
3315 (N–H), 3006 (C–H; aromatic), 2980 (C–H; aliphatic), 1698
(C¼O; amide), 1608 (C¼C; aromatic) and 1219 (C–N). 1H-NMR
(DMSO, ppm); 1.46 (t, 3H, –OCH2CH3, J¼ 7.2 Hz), 2.29 (s, 3H,
–Ph–CH3), 2.81 (t, 4H, piperazine H2,6, J¼ 5.2 Hz), 3.23 (t, 4H,
piperazine H3,5, J¼ 5.2 Hz), 2.29 (s, 2H, –COCH2N–), 4.06–4.12
(m, 2H, –OCH2CH3), 6.86 (d, 2H, phenyl H2,6, J¼ 8.8 Hz), 7.03–
7.06 (dd, 2H, phenyl H3,5, J1¼ 2.4 Hz, J2¼ 8.8 Hz), 7.09–7.11
(dd, 1H, benzothiazole H5, J¼ 8.8 Hz), 7.26–7.29 (m, 1H,
benzothiazole H7), 7.67 (d, 1H, benzothiazol H4, J¼ 8.8 Hz),
10.36 (bs, 1H, –NHCOCH2–). Anal Calcd for C22H26N4O2S
(410.532): C, 64.05; H, 6.84; N, 13.58; S, 7.77. Found: C, 64.04;
H, 6.82; N, 13.55; S, 7.80.
N-(6-ethoxybenzothiazol-2-yl)-2-[4-(o-chlorophenyl)piperaziny-
l]acetamide (2b)
Light brown colored powder. 47.5% (0.512 g), m.p. above 300 C.
UV (MeOH, lmax, nm); 293 (log ": 4.16). FT-IR (KBr, cm
1);
3334 (N–H), 3065 (C–H; aromatic), 2971 (C–H; aliphatic), 1702
(C¼O; amide), 1605 (C¼C; aromatic), 1226 (C–N). 1H-NMR
(DMSO, ppm); 1.47 (t, 3H, –OCH2CH3, J¼ 7.2 Hz), 2.85 (t, 4H,
piperazine H2,6, J¼ 4.4 Hz), 3.17 (bs, 4H, piperazine H3,5), 3.36
(s, 2H, –COCH2N–), 4.07–4.12 (m, 2H, –OCH2CH3), 6.99–7.09
(m, 3H, phenyl H4,5,6), 7.25 (d, 1H, phenyl H3, J¼ 1.2 Hz),
7.26–7.29 (m, 1H, benzothiazole H7), 7.38–7.39 (dd,
1H, benzothiazole H5, J1¼ 1.2 Hz, J2¼ 8 Hz), 7.68 (d, 1H,
benzothiazol H4, J¼ 8.8 Hz), 10.41 (bs, 1H, –NHCOCH2–).
Anal Calcd for C21H23ClN4O2S (430.951): C, 58.25; H, 5.82;
N, 12.94; O, 7.39; S, 7.41. Found: C, 58.22; H, 5.82; N, 12.94;
S, 7.40.

































Beige colored powder. 42.7% (0.45 g), m.p. above 300 C. UV
(MeOH, lmax, nm); 292 (log ": 4.21). FT-IR (KBr, cm
1); 3194
(N–H), 3060 (C–H; aromatic), 2972 (C–H; aliphatic), 2215
(CN), 1699 (C¼O; amide), 1605 (C¼C; aromatic), 1225 (C–N).
1H-NMR (DMSO, ppm); 1.46 (t, 3H, –OCH2CH3, J¼ 7.2 Hz),
2.80 (t, 4H, piperazine H2,6, J¼ 5.2 Hz), 3.42 (t, 4H, piperazine
H3,5, J¼ 5.2 Hz), 3.35 (s, 2H, –COCH2N–), 4.06–4.12 (m, 2H,
–OCH2CH3), 6.88 (d, 2H, phenyl H2,6, J¼ 8.8 Hz), 7.53 (d, 2H,
phenyl H3,5, J1¼ 8.8 Hz), 7.03–7.06 (dd, 1H, benzothiazole H5,
J1¼ 2.4 Hz, J2¼ 8.6 Hz), 7.26–7.29 (m, 1H, benzothiazole H7),
7.67 (d, 1H, benzothiazole H4, J¼ 8.8 Hz), 10.28 (bs, 1H,
–NHCOCH2–). Anal Calcd for C22H23N5O2S (421.515): C,




Beige colored powder. 25.6% (0.27 g), m.p. above 300 C. UV
(MeOH, lmax, nm); 290 (log ": 4.23). FT-IR (KBr, cm
1); 3290
(N–H), 3068 (C–H; aromatic), 2825 (C–H; aliphatic), 2221
(CN), 1703 (C¼O; amide), 1605 (C¼C; aromatic), 1225 (C–N).
1H-NMR (DMSO, ppm); 1.45 (t, 3H, –OCH2CH3, J¼ 7.2 Hz),
2.88 (t, 4H, piperazine H2,6, J¼ 4.4 Hz), 3.31 (t, 4H, piperazine
H3,5, J¼ 4.4 Hz), 3.38 (s, 2H, –COCH2N–), 4.07–4.12 (m, 2H,
–OCH2CH3), 7.03–7.09 (m, 3H, phenyl H4,5,6), 7.51–7.56 (m, 1H,
phenyl H3), 7.26–7.29 (m, 1H, benzothiazole H7), 7.58–7.61 (dd,
1H, benzothiazole H5, J1¼ 1.6 Hz, J2¼ 8 Hz), 7.68 (d, 1H,
benzothiazol H4, J¼ 9.2 Hz), 10.36 (bs, 1H, –NHCOCH2–).
Anal Calcd for C22H23N5O2S (421.515): C, 62.39; H, 5.95; N,
16.54; S, 7.57. Found: C, 62.37; H, 5.96; N, 16.55; S, 7.58.
Biological activity
The cytotoxic activity of the synthesized compounds 1a–f and
2a–d was investigated on liver (HUH-7), breast (MCF-7) and
colon (HCT-116) cancer cell lines, by means of sulphorhodamine
B (SRB) assays in triplicate. As shown in Table 2, all tested
compounds were screened with mean 50% growth inhibition
concentration (GI50) in micromolar concentration range. The
cytotoxicity results show that most of the substituted benzothia-
zole-piperazine derivatives are active against tested cancer cell
lines. Further investigation of compound 1d by Hoechst staining
and FACS revealed that this compound causes apoptosis by cell
cycle arrest at subG1 phase.
Discussion
The synthesis of benzothiazole-piperazine derivatives is outlined
in Figure 1. The final compounds are obtained by two stages
which are N-acetylation of the primary amine and N-alkylation of
the secondary amine. In order to obtain target compounds, firstly
it is necessary to synthesize 2-chloro-N-(6-methylbenzothiazole-
2-yl)acetamide (1) and 2-chloro-N-(6-ethoxybenzothiazole-2-
yl)acetamide (2) starting from 2-amino-6-methylbenzothiazole
and 2-amino-6-ethoxybenzothiazole, respectively. Finally, com-
pounds 1 and 2 are reacted with various piperazine derivatives
under basic conditions in which piperazines are N-alkylated to
yield the final products. Structural and physical properties of the
synthesized benzothiazole-piperazine derivatives are summarized
in Table 1.
Synthesized compounds were identified with UV, IR and
1H-NMR spectra. In UV spectrum of compounds there is one
significant band at 290 nm which represents n!* transition of
the series. In IR spectrum of benzothiazole-piperazine derivatives,
characteristic N–H stretching band was observed nearly at
3330 cm1. Other stretching bands were observed approximately
at 3050 cm1 (C–H; aromatic), 2980 cm1 (C–H; aliphatic),
1700 cm1 (C¼O; amide), 1605 cm1 (C¼C; aromatic) and
1240 cm1 (C–N). In 1H-NMR spectra of benzothiazole-pipera-
zine derivatives, the protons of piperazine were seen approxi-
mately at 2.70 and 3.33 ppm as triplets (J¼ 8.2 Hz). Amide N–H
gave broad singlet nearly at 10.33 ppm. Methylene protons of
–COCH2N– gave singlet nearly at 3.35 ppm. The protons of








































Figure 1. Synthesis of compounds 1a–f and 2a–d.
Table 1. Structural and physical properties of compounds 1a–f and 2a–d.
Compounds R1 R2 M.P. (
C) Yield % Log P*
1a Methyl 2-Methoxyphenyl 121.9y 48 4.15
1b Methyl 2-Methoxyethyl 81.1 12 2.04
1c Methyl Cyclohexyl 181.3 18 3.74
1d Methyl 4-Pyridyl 100.8 22 2.94
1e Methyl 3,4-Dichlorophenyl 243.8 16 5.39
1f Methyl 4-Chlorobenzyl 189.6 12 4.49
2a Ethoxy 4-Methylphenyl 146.7 36.5 4.76
2b Ethoxy 2-Chlorophenyl 4300 47.5 4.83
2c Ethoxy 4-Cyanophenyl 4300 42.7 4.31
2d Ethoxy 2-Cyanophenyl 4300 25.6 4.31
*Log P were calculated using ChemDraw Ultra V.9.0 (ChembridgeSoft
Corp., Cambridge, MA).
yMelting point of compound 1a in the original reference15 is reported as
122–124 C.































(J¼ 8 Hz) (H4) at 7.25–7.27 ppm as multiplets (H5) and 7.62 ppm
as singlets (H7). Methyl protons of Ar-CH3 (1a–f) gave
singlet nearly at 2.48 ppm. Methyl protons of Ar-OCH2CH3
(2a–d) gave triplets nearly at 1.45 (J¼ 7.2 Hz) ppm and
methylene protons of Ar-OCH2CH3 (2a–d) gave multiplets
nearly at 4.06–4.12 ppm.
In HCT-116 colorectal cancer cell line, the GI50 values for
benzothiazole-piperazine derivatives were in range of 4–25mM.
Among series, 4-methylphenyl substituted compound 2a
(GI50: 4.5mM) had the highest cytotoxicity. Cyclohexyl ring
(1c, GI50: 15.1 mM) lowered the activity of 6-methylbenzothiazole
derivatives. In addition, compounds 2c (GI50: 6.3 mM) and 2d
(GI50: 25.3 mM) showed that electron withdrawing cyano group
should be on para position rather than ortho position of phenyl
ring for higher cytotoxicity.
In MCF-7 breast cancer cell line, the GI50 values
for benzothiazole-piperazine derivatives were in range of
9–60 mM. Among series, 4-pyridyl substituted compound 1d
(GI50: 9.2mM) and 2-methoxyphenyl substituted compound
1a (GI50: 15.1 mM) had highest cytotoxicities. Also compounds
1b (R2: 2-methoxyethyl) and 1f (R2: 4-chlorobenzyl) showed no
inhibition against MCF-7 cell line.
The activity data showed that all synthesized compounds have
good cytotoxic activity against HUH-7 liver cancer cell line in
range of 3–10mM. The most active compound against this cell
Figure 2. Fluorescence images of liver cancer (HUH7) cellsa,b. aCells were placed on cover slips and treated with GI50 concentration of compound 1d

















Figure 3. Cell cycle distribution analysis of compound 1d.
Table 2. Cytotoxic activity data for compounds 1a–f and 2a–d.
Cancer cell line (GI50, mM)
Compounds HCT-116 R2 MCF-7 R2 HUH-7 R2
1a 4.8 1.0 15.1 1.0 5.7 1.0
1b 7.7 0.8 no inh – 10.7 0.8
1c 15.1 0.9 26.9 0.8 7.9 0.9
1d 7.9 0.9 9.2 0.9 3.1 0.9
1e 8.0 0.9 16.6 0.9 9.7 1.0
1f 5.0 0.8 no inh – 7.0 0.9
2a 4.5 1.0 61.4 0.9 9.4 1.0
2b 5.8 0.9 20.4 0.9 6.5 0.9
2c 6.3 0.8 29.8 0.9 7.4 0.8
2d 25.3 0.9 19.8 0.9 6.7 0.9
5-FU 30.66 3.51 18.67































line was 1d (R2: 4-pyridyl, GI50: 3.1mM). Compounds 1a
(R2: 2-methoxyphenyl, GI50: 5.7 mM) and 2b (R2: 2-chlorophenyl,
GI50: 6.5mM) were other highly active derivatives against HUH-7
cell line.
We did not find any significant correlation between GI50
values and log P values of the compounds 1a–f and 2a–d
(Table 1). Therefore, the difference in lipophilicity may not be a
significant factor for the difference in cytotoxicity of the series in
our study.
Compound 1d (R1¼methyl, R2¼ 4-pyridyl) was found highly
active against all tested cancer cell lines. Therefore, we carried
out Hoechst staining (Figure 2) and Fluorescence-Activated Cell
Sorting Analysis (FACS, Figure 3) for compound 1d to gain
insight into its mechanism of action.
To examine the type of cell death, induction of apoptosis
was investigated by Hoechst staining. Human liver cancer cell
line HUH-7 was treated with compound 1d. Hoechst staining
showed condensed nuclei that indicated apoptotic cells in
treated samples. Whereas in HUH-7 cell group treated with
DMSO, no apoptotic cells were present. This result indicated that
apoptosis is most likely to be the cell death type induced by
compound 1d.
The effect of the compound 1d on the cell cycle was further
characterized by FACS analysis, using a propidium iodide stain.
This analysis revealed elevated subG1 phased cells indicating the
subG1 cell cycle arrest compared to control cells treated with
DMSO. This result that indicates the presence of cells arrested at
subG1 phase supports the induction of apoptotic cell death in
those cells treated with compound 1d.
Conclusions
In this study, ten benzothiazole-piperazine derivatives were
synthesized, purified and characterized by various analysis
methods. In vitro cytotoxic activities were screened against
colorectal (HCT-116), breast (MCF-7), and hepatocellular
(HUH-7) cancer cell lines by sulphorhodamine B assay. Most of
the compounds showed high cytotoxic activity against all tested
cell lines. Hoechst staining and Fluorescence-activated cell
sorting analysis, were also performed with compound 1d to
understand the mechanism of cytotoxicity which revealed that this
compound causes apoptosis by cell cycle arrest at subG1 phase.
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